Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy

G. Paolo Rizzardi, Alexandre Harari, Brunella Capiluppi, Giuseppe Tambussi, Kim Ellefsen, Donatella Ciuffreda, Patrick Champagne, Pierre Alexandre Bart, Jean Philippe Chave, Adriano Lazzarin, Giuseppe Pantaleo

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Primary HIV-1 infection causes extensive immune activation, during which CD4+ T cell activation supports massive HIV-1 production. We tested the safety and the immune-modulating effects of combining cyclosporin A (CsA) treatment with highly active antiretroviral therapy (HAART) during primary HIV-1 infection. Nine adults with primary HIV-1 infection were treated with CsA along with HAART. At week 8, all patients discontinued CsA but maintained HAART. Viral replication was suppressed to a comparable extent in the CsA + HAART cohort and in 29 control patients whose primary infection was treated with HAART alone. CsA restored normal CD4+ T cell levels, both in terms of percentage and absolute numbers. The increase in CD4+ T cells was apparent within a week and persisted throughout the study period. CsA was not detrimental to vires-specific CD8+ or CD4+ T cell responses. At week 48, the proportion of IFN-γ-secreting CD4+ and CD4+CCR7- T cells was significantly higher in the CsA + HAART cohort than in the HAART-alone cohort. In conclusion, rapid shutdown of T cell activation in the early phases of primary HIV-1 infection can have long-term beneficial effects and establish a more favorable immunologic set-point. Appropriate, immune-based therapeutic interventions may represent a valuable complement to HAART for treating HIV infection.

Original languageEnglish
Pages (from-to)681-688
Number of pages8
JournalJournal of Clinical Investigation
Volume109
Issue number5
DOIs
Publication statusPublished - 2002

Fingerprint

Highly Active Antiretroviral Therapy
Cyclosporine
HIV Infections
HIV-1
T-Lymphocytes
Therapeutics
Safety
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. / Paolo Rizzardi, G.; Harari, Alexandre; Capiluppi, Brunella; Tambussi, Giuseppe; Ellefsen, Kim; Ciuffreda, Donatella; Champagne, Patrick; Bart, Pierre Alexandre; Chave, Jean Philippe; Lazzarin, Adriano; Pantaleo, Giuseppe.

In: Journal of Clinical Investigation, Vol. 109, No. 5, 2002, p. 681-688.

Research output: Contribution to journalArticle

Paolo Rizzardi, G, Harari, A, Capiluppi, B, Tambussi, G, Ellefsen, K, Ciuffreda, D, Champagne, P, Bart, PA, Chave, JP, Lazzarin, A & Pantaleo, G 2002, 'Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy', Journal of Clinical Investigation, vol. 109, no. 5, pp. 681-688. https://doi.org/10.1172/JCI200214522
Paolo Rizzardi, G. ; Harari, Alexandre ; Capiluppi, Brunella ; Tambussi, Giuseppe ; Ellefsen, Kim ; Ciuffreda, Donatella ; Champagne, Patrick ; Bart, Pierre Alexandre ; Chave, Jean Philippe ; Lazzarin, Adriano ; Pantaleo, Giuseppe. / Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. In: Journal of Clinical Investigation. 2002 ; Vol. 109, No. 5. pp. 681-688.
@article{bbebeeb46ee644dfb0c0280e9ced1c7e,
title = "Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy",
abstract = "Primary HIV-1 infection causes extensive immune activation, during which CD4+ T cell activation supports massive HIV-1 production. We tested the safety and the immune-modulating effects of combining cyclosporin A (CsA) treatment with highly active antiretroviral therapy (HAART) during primary HIV-1 infection. Nine adults with primary HIV-1 infection were treated with CsA along with HAART. At week 8, all patients discontinued CsA but maintained HAART. Viral replication was suppressed to a comparable extent in the CsA + HAART cohort and in 29 control patients whose primary infection was treated with HAART alone. CsA restored normal CD4+ T cell levels, both in terms of percentage and absolute numbers. The increase in CD4+ T cells was apparent within a week and persisted throughout the study period. CsA was not detrimental to vires-specific CD8+ or CD4+ T cell responses. At week 48, the proportion of IFN-γ-secreting CD4+ and CD4+CCR7- T cells was significantly higher in the CsA + HAART cohort than in the HAART-alone cohort. In conclusion, rapid shutdown of T cell activation in the early phases of primary HIV-1 infection can have long-term beneficial effects and establish a more favorable immunologic set-point. Appropriate, immune-based therapeutic interventions may represent a valuable complement to HAART for treating HIV infection.",
author = "{Paolo Rizzardi}, G. and Alexandre Harari and Brunella Capiluppi and Giuseppe Tambussi and Kim Ellefsen and Donatella Ciuffreda and Patrick Champagne and Bart, {Pierre Alexandre} and Chave, {Jean Philippe} and Adriano Lazzarin and Giuseppe Pantaleo",
year = "2002",
doi = "10.1172/JCI200214522",
language = "English",
volume = "109",
pages = "681--688",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy

AU - Paolo Rizzardi, G.

AU - Harari, Alexandre

AU - Capiluppi, Brunella

AU - Tambussi, Giuseppe

AU - Ellefsen, Kim

AU - Ciuffreda, Donatella

AU - Champagne, Patrick

AU - Bart, Pierre Alexandre

AU - Chave, Jean Philippe

AU - Lazzarin, Adriano

AU - Pantaleo, Giuseppe

PY - 2002

Y1 - 2002

N2 - Primary HIV-1 infection causes extensive immune activation, during which CD4+ T cell activation supports massive HIV-1 production. We tested the safety and the immune-modulating effects of combining cyclosporin A (CsA) treatment with highly active antiretroviral therapy (HAART) during primary HIV-1 infection. Nine adults with primary HIV-1 infection were treated with CsA along with HAART. At week 8, all patients discontinued CsA but maintained HAART. Viral replication was suppressed to a comparable extent in the CsA + HAART cohort and in 29 control patients whose primary infection was treated with HAART alone. CsA restored normal CD4+ T cell levels, both in terms of percentage and absolute numbers. The increase in CD4+ T cells was apparent within a week and persisted throughout the study period. CsA was not detrimental to vires-specific CD8+ or CD4+ T cell responses. At week 48, the proportion of IFN-γ-secreting CD4+ and CD4+CCR7- T cells was significantly higher in the CsA + HAART cohort than in the HAART-alone cohort. In conclusion, rapid shutdown of T cell activation in the early phases of primary HIV-1 infection can have long-term beneficial effects and establish a more favorable immunologic set-point. Appropriate, immune-based therapeutic interventions may represent a valuable complement to HAART for treating HIV infection.

AB - Primary HIV-1 infection causes extensive immune activation, during which CD4+ T cell activation supports massive HIV-1 production. We tested the safety and the immune-modulating effects of combining cyclosporin A (CsA) treatment with highly active antiretroviral therapy (HAART) during primary HIV-1 infection. Nine adults with primary HIV-1 infection were treated with CsA along with HAART. At week 8, all patients discontinued CsA but maintained HAART. Viral replication was suppressed to a comparable extent in the CsA + HAART cohort and in 29 control patients whose primary infection was treated with HAART alone. CsA restored normal CD4+ T cell levels, both in terms of percentage and absolute numbers. The increase in CD4+ T cells was apparent within a week and persisted throughout the study period. CsA was not detrimental to vires-specific CD8+ or CD4+ T cell responses. At week 48, the proportion of IFN-γ-secreting CD4+ and CD4+CCR7- T cells was significantly higher in the CsA + HAART cohort than in the HAART-alone cohort. In conclusion, rapid shutdown of T cell activation in the early phases of primary HIV-1 infection can have long-term beneficial effects and establish a more favorable immunologic set-point. Appropriate, immune-based therapeutic interventions may represent a valuable complement to HAART for treating HIV infection.

UR - http://www.scopus.com/inward/record.url?scp=0036192919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036192919&partnerID=8YFLogxK

U2 - 10.1172/JCI200214522

DO - 10.1172/JCI200214522

M3 - Article

C2 - 11877476

AN - SCOPUS:0036192919

VL - 109

SP - 681

EP - 688

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -